Sign in

CD19 CAR-T cell therapy & Stiff Person Syndrome

Last updated: 17 Nov 2026 incl. AI

Sources: PubMed, Neurology, Transplantation and Cellular Therapy

Does CD19 CAR-T cell therapy treat stiff person syndrome?

Checked

Posts say CAR-T cell therapy aimed at CD19 helps people with Stiff Person Syndrome, a rare disease with muscle stiffness and painful spasms.

Some results in people look good, but it is not proven that CD19 CAR-T cell therapy treats stiff person syndrome.

What studies show

As of , no study fully proves that CD19 CAR-T cell therapy treats stiff person syndrome. We found 3 published papers on CD19 CAR-T cell therapy and stiff person syndrome. They were published between 2024 and 2026. 1 of them is a study in people. The papers do not say how many people took part. None of them was a fair test in which chance decided who got it and who did not. None was a study in animals, and none was only in cells in the lab.

Trials in people

A 2026 US study tested a CAR-T therapy in adults with Stiff Person Syndrome. These adults had not responded enough to other immune treatments. Every patient got the therapy, and there was no comparison group. It was a mid-stage test in people, run at 3 sites.

Other papers

A 2026 report on a study of 26 patients says walking time improved at week 16. A 2024 case report from Germany described one woman, aged 69. Her walking went from under 50 meters a day to over 6 kilometers within 3 months. A 2025 case report described another woman, aged 62, who could walk 500 meters by month 6. Single case reports cannot show that the therapy caused the improvement.

What this means for you

Our verdict: Partly true.

Early results in people look good, but every patient got the therapy. No study has compared it with a group that did not get it. So the claim is partly true.

Do not stop or change your treatment because of a story about CD19 CAR-T cell therapy. A study in people is not proof that it helps you. If you are thinking about CD19 CAR-T cell therapy, talk to your care team first.

This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.

We searched 18 scientific databases for research from the last 10 years (since 17 Nov 2016).

Sources

  1. Mivocabtagene Autoleucel CD19 Chimeric Antigen Receptor T-Cell Therapy in Stiff Person Syndrome: A Nonrandomized Clinical Trial. JAMA Neurol 2026. Study in people. PubMed
  2. Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8). Neurology 2026. Other paper. Neurology
  3. Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008). Neurology 2026. Other paper. Neurology
  4. International Delphi Survey of Clinical Practice in Stiff Person Syndrome and Related Disorders: Treatment and Monitoring. Neurology 2026. Other paper. Neurology
  5. Design of KYSA-8, A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment-Refractory Stiff-Person Syndrome (P2-8.018). Neurology 2025. Other paper. Neurology
  6. Anti-CD19 CAR T-Cell Therapy in Advanced Stiff-Person Syndrome and Concomitant Myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm 2025. Other paper. PubMed
  7. Successful Generation of Anti-CD19 CAR T-Cells (KYV-101) for Clinical Use in Patients with Clinically Diverse Autoimmune Disorders. Transplantation and Cellular Therapy 2025. Other paper. Transplantation and Cellular Therapy
  8. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci U S A 2024. Other paper. PubMed

Research you can look at next

Open trials and published studies linked to this claim, each with its source and date.

This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.